Lung Involvement in Systemic Sclerosis—From Pathogenesis to Prediction
Open Access
Abstract
Systemic sclerosis (SSc) is a rare, multifactorial autoimmune disease characterized by widespread vascular damage and fibrosis. Pulmonary involvement is a significant manifestation of SSc, contributing to considerable morbidity and mortality. Therefore, identifying reliable biomarkers is of the utmost importance. This review explores emerging biomarkers to enhance diagnostic accuracy, prognostic assessment, and disease monitoring in SSc lung involvement. We discuss recent findings in immunological biomarkers, inflammatory indicators, and other parameters that can function as potential diagnostic and prognostic tools. A comprehensive understanding of these biomarkers could result in earlier and more accurate detection of pulmonary complications in SSc, aiding in timely intervention. Furthermore, we explore the advances in disease monitoring through innovative biomarkers, focusing on their roles in disease activity and treatment response. Integrating these novel biomarkers into current clinical practice and therapeutic protocols through clinical trials can revolutionize the management of SSc-related lung disease, ultimately improving patient outcomes and quality of life.Keywords
Funding Information
- European Union-NextGenerationEU (BG-RRP-2.004-0008)
This publication has 74 references indexed in Scilit:
- Pulmonary hypertension in patients with interstitial lung disease: a tool for early detectionPulmonary Circulation, 2022
- Systemic Sclerosis-Specific Antibodies: Novel and Classical BiomarkersClinical Reviews in Allergy & Immunology, 2022
- Rehabilitation Interventions in Systemic Sclerosis: A Systematic Review and Future DirectionsArthritis Care & Research, 2021
- Current Concepts on the Pathogenesis of Systemic SclerosisClinical Reviews in Allergy & Immunology, 2021
- Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung DiseaseArthritis & Rheumatology, 2021
- Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic reviewRheumatology International, 2021
- Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanismsRheumatology International, 2020
- Antinuclear Antibodies in Systemic Sclerosis: an UpdateClinical Reviews in Allergy & Immunology, 2019
- A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaArthritis & Rheumatism, 2006
- A comparison between anti‐Th/To– and anticentromere antibody–positive systemic sclerosis patients with limited cutaneous involvementArthritis & Rheumatism, 2003